Amid an 18 percent increase in cancer drug sales, J&J executives shared hopes that recent overall survival data for the drug combo will be practice changing.

In the trial, researchers are evaluating Scancell's DNA cancer vaccines SCIB1 and iSCIB1+ alongside immunotherapy.

After VERVE-102 showed the ability to lower LDL-C and PCSK9 in the Heart-2 trial, the firm said it will advance the therapy to a Phase II study later this year.